S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58

AngioDynamics (ANGO) Stock Forecast, Price & News

-0.23 (-1.18%)
(As of 05/19/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
195,333 shs
Average Volume
215,275 shs
Market Capitalization
$744.59 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ANGO News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

AngioDynamics logo

About AngioDynamics

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$291.01 million
Cash Flow
$0.72 per share
Book Value
$11.52 per share


Net Income
$-31.55 million
Pretax Margin




Free Float
Market Cap
$744.59 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.12 out of 5 stars

Medical Sector

459th out of 1,420 stocks

Surgical & Medical Instruments Industry

54th out of 138 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions

Is AngioDynamics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AngioDynamics stock.
View analyst ratings for AngioDynamics
or view top-rated stocks.

When is AngioDynamics' next earnings date?

AngioDynamics is scheduled to release its next quarterly earnings announcement on Tuesday, July 12th 2022.
View our earnings forecast for AngioDynamics

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings data on Thursday, April, 7th. The medical instruments supplier reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.04. The medical instruments supplier earned $74 million during the quarter, compared to the consensus estimate of $76.32 million. AngioDynamics had a negative trailing twelve-month return on equity of 0.12% and a negative net margin of 12.99%. The firm's revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.02 EPS.
View AngioDynamics' earnings history

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics issued an update on its FY 2022 earnings guidance on Thursday, April, 21st. The company provided earnings per share (EPS) guidance of $-0.020-$0.020 for the period, compared to the consensus estimate of $-0.010. The company issued revenue guidance of $310 million-$315 million, compared to the consensus revenue estimate of $313.65 million.

What price target have analysts set for ANGO?

2 equities research analysts have issued 12 month target prices for AngioDynamics' shares. Their forecasts range from $32.00 to $40.00. On average, they anticipate AngioDynamics' share price to reach $36.00 in the next twelve months. This suggests a possible upside of 87.2% from the stock's current price.
View analysts' price targets for AngioDynamics
or view top-rated stocks among Wall Street analysts.

Who are AngioDynamics' key executives?
AngioDynamics' management team includes the following people:
  • Mr. James C. Clemmer, CEO, Pres & Director (Age 58, Pay $1.91M)
  • Mr. Stephen A. Trowbridge, Exec. VP & CFO (Age 48, Pay $812.99k) (LinkedIn Profile)
  • Mr. David D. Helsel, Sr. VP of Global Operations and R&D (Age 58, Pay $664.29k) (LinkedIn Profile)
  • Mr. Chad T. Campbell, Sr. VP & GM of Vascular Access Global Bus. Unit (Age 51, Pay $589.75k)
  • Mr. Warren G. Nighan, Sr. VP of Quality & Regulatory Affairs (Age 53, Pay $622.11k)
  • Mr. Richard C. Rosenzweig, Sr. VP, Gen. Counsel & Company Sec. (Age 55)
  • Mr. Benjamin H. Davis, Sr. VP of Bus. Devel. (Age 58)
  • Ms. Marna I. Bronfen-Moore, Sr. VP of HR (Age 55)
  • Ms. Kim L. Seabury, Sr. VP of Information Technology (Age 55)
  • Mr. Scott Centea, Sr. VP & GM of Vascular Interventions and Therapies & Peripheral Artery Disease (Age 44) (LinkedIn Profile)
What is James C. Clemmer's approval rating as AngioDynamics' CEO?

27 employees have rated AngioDynamics CEO James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among AngioDynamics' employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.20%), Victory Capital Management Inc. (7.33%), Dimensional Fund Advisors LP (7.10%), Vanguard Group Inc. (6.58%), Polar Capital Holdings Plc (4.86%) and State Street Corp (4.14%). Company insiders that own AngioDynamics stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends for AngioDynamics

Which institutional investors are selling AngioDynamics stock?

ANGO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Renaissance Technologies LLC, Invesco Ltd., Raymond James & Associates, Prudential Financial Inc., Lapides Asset Management LLC, and Northern Trust Corp. Company insiders that have sold AngioDynamics company stock in the last year include Chad Thomas Campbell, Dave Helsel, Scott Centea, and Wesley Johnson.
View insider buying and selling activity for AngioDynamics
or view top insider-selling stocks.

Which institutional investors are buying AngioDynamics stock?

ANGO stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Polar Capital Holdings Plc, Polar Asset Management Partners Inc., Loomis Sayles & Co. L P, JPMorgan Chase & Co., Frontier Capital Management Co. LLC, Dimensional Fund Advisors LP, and Dynamic Technology Lab Private Ltd. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer, and Stephen A Trowbridge.
View insider buying and selling activity for AngioDynamics
or or view top insider-buying stocks.

How do I buy shares of AngioDynamics?

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $19.23.

How much money does AngioDynamics make?

AngioDynamics has a market capitalization of $744.59 million and generates $291.01 million in revenue each year. The medical instruments supplier earns $-31.55 million in net income (profit) each year or ($1.03) on an earnings per share basis.

How many employees does AngioDynamics have?

AngioDynamics employs 800 workers across the globe.

Does AngioDynamics have any subsidiaries?

The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.

When was AngioDynamics founded?

AngioDynamics was founded in 1988.

What is AngioDynamics' official website?

The official website for AngioDynamics is www.angiodynamics.com.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at [email protected], or via fax at 518-795-1401.

This page was last updated on 5/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.